Cargando…
The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and degenerative disease with axonal damage and demyelination as its main features. Its dual neurological and autoimmune nature makes it a disease that is difficult to treat. Treatments that simultaneously stop the immune response while...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694690/ https://www.ncbi.nlm.nih.gov/pubmed/36430856 http://dx.doi.org/10.3390/ijms232214378 |
_version_ | 1784837866130505728 |
---|---|
author | Benítez-Fernández, Rocio Gil, Carmen Guaza, Carmen Mestre, Leyre Martínez, Ana |
author_facet | Benítez-Fernández, Rocio Gil, Carmen Guaza, Carmen Mestre, Leyre Martínez, Ana |
author_sort | Benítez-Fernández, Rocio |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and degenerative disease with axonal damage and demyelination as its main features. Its dual neurological and autoimmune nature makes it a disease that is difficult to treat. Treatments that simultaneously stop the immune response while protecting and repairing the nervous system are urgent. That is of utmost importance for the primary progressive multiple sclerosis (PPMS), a rare and severe variant of MS, characterized by worsening neurological function from the onset of symptoms. In this sense, inhibitors of glycogen synthase kinase 3β (GSK3β) and phosphodiesterase 7 (PDE7) have recently shown great therapeutic potential for the treatment of demyelinating diseases. Here we investigated a dual inhibitor of these two targets, the small molecule VP3.15, in a preclinical model, which resembles primary-progressive MS (PPMS), the Theiler’s mouse encephalomyelitis virus-induced demyelinated disease (TMEV-IDD). In our study, VP3.15 ameliorates the disease course improving motor deficits of infected mice. Chronic treatment with VP3.15 also showed significant efficacy in the immunomodulation process, as well as in the proliferation and differentiation of oligodendroglial precursors, improving the preservation of myelin and axonal integrity. Therefore, our results support a treatment with the safe VP3.15 as an integrative therapeutic strategy for the treatment of PPMS. |
format | Online Article Text |
id | pubmed-9694690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96946902022-11-26 The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis Benítez-Fernández, Rocio Gil, Carmen Guaza, Carmen Mestre, Leyre Martínez, Ana Int J Mol Sci Article Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and degenerative disease with axonal damage and demyelination as its main features. Its dual neurological and autoimmune nature makes it a disease that is difficult to treat. Treatments that simultaneously stop the immune response while protecting and repairing the nervous system are urgent. That is of utmost importance for the primary progressive multiple sclerosis (PPMS), a rare and severe variant of MS, characterized by worsening neurological function from the onset of symptoms. In this sense, inhibitors of glycogen synthase kinase 3β (GSK3β) and phosphodiesterase 7 (PDE7) have recently shown great therapeutic potential for the treatment of demyelinating diseases. Here we investigated a dual inhibitor of these two targets, the small molecule VP3.15, in a preclinical model, which resembles primary-progressive MS (PPMS), the Theiler’s mouse encephalomyelitis virus-induced demyelinated disease (TMEV-IDD). In our study, VP3.15 ameliorates the disease course improving motor deficits of infected mice. Chronic treatment with VP3.15 also showed significant efficacy in the immunomodulation process, as well as in the proliferation and differentiation of oligodendroglial precursors, improving the preservation of myelin and axonal integrity. Therefore, our results support a treatment with the safe VP3.15 as an integrative therapeutic strategy for the treatment of PPMS. MDPI 2022-11-19 /pmc/articles/PMC9694690/ /pubmed/36430856 http://dx.doi.org/10.3390/ijms232214378 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Benítez-Fernández, Rocio Gil, Carmen Guaza, Carmen Mestre, Leyre Martínez, Ana The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis |
title | The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis |
title_full | The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis |
title_fullStr | The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis |
title_full_unstemmed | The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis |
title_short | The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis |
title_sort | dual pde7-gsk3β inhibitor, vp3.15, as neuroprotective disease-modifying treatment in a model of primary progressive multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694690/ https://www.ncbi.nlm.nih.gov/pubmed/36430856 http://dx.doi.org/10.3390/ijms232214378 |
work_keys_str_mv | AT benitezfernandezrocio thedualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT gilcarmen thedualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT guazacarmen thedualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT mestreleyre thedualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT martinezana thedualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT benitezfernandezrocio dualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT gilcarmen dualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT guazacarmen dualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT mestreleyre dualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis AT martinezana dualpde7gsk3binhibitorvp315asneuroprotectivediseasemodifyingtreatmentinamodelofprimaryprogressivemultiplesclerosis |